Scholarlink

Background/Objectives <p>To characterize sedative and analgesic use in NICU patients with grade 3 bronchopulmonary dysplasia (BPD) in relation to respiratory support and neurodevelopmental therapies.</p> Subjects/Methods <p>Point-prevalence survey across 22 NICUs of infants &lt;24 months corrected age with grade 3 BPD who had never been discharged. Exclusions included recent sepsis, tracheostomy, or major surgery. Data were analyzed descriptively.</p> Results <p>Among 141 infants, 97 (69%) received ≥1 sedative within 48 hours; 73 (75%) received multiple (mean 2.8 ± 1.6). Alpha-agonizts (n=67) and benzodiazepines (n=65) were most common, with 27 infants receiving an alpha-agonist, opioid, and benzodiazepine combination. Sedative exposure and medication count correlated with higher respiratory support (p&lt;0.001) and FiO₂ (r=0.28, p&lt;0.01). Sedation was associated with fewer completed therapy sessions (z=3.3, p&lt;0.001).</p> Conclusion <p>Sedation and polypharmacy were frequent among infants with severe BPD and linked to reduced therapy participation, highlighting the need to assess prescribing rationale and neurodevelopmental impacts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sedative use in infants with grade 3 bronchopulmonary dysplasia (BPD) and associations with neurodevelopmental therapies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Thomas J. Davis,
  • Gangaram Akangire,
  • Brianna K. Brei,
  • Matthew Coyle,
  • Bridget DiPrisco,
  • Tara DuPont,
  • Susan Gage,
  • Melissa Hanin,
  • Melissa House,
  • Khanh Lai,
  • Audrey N. Miller,
  • Divya Rana,
  • Karishma Rao,
  • Meaghan A. Ransom,
  • Laura Sillers,
  • Sara B. DeMauro

摘要

Background/Objectives

To characterize sedative and analgesic use in NICU patients with grade 3 bronchopulmonary dysplasia (BPD) in relation to respiratory support and neurodevelopmental therapies.

Subjects/Methods

Point-prevalence survey across 22 NICUs of infants <24 months corrected age with grade 3 BPD who had never been discharged. Exclusions included recent sepsis, tracheostomy, or major surgery. Data were analyzed descriptively.

Results

Among 141 infants, 97 (69%) received ≥1 sedative within 48 hours; 73 (75%) received multiple (mean 2.8 ± 1.6). Alpha-agonizts (n=67) and benzodiazepines (n=65) were most common, with 27 infants receiving an alpha-agonist, opioid, and benzodiazepine combination. Sedative exposure and medication count correlated with higher respiratory support (p<0.001) and FiO₂ (r=0.28, p<0.01). Sedation was associated with fewer completed therapy sessions (z=3.3, p<0.001).

Conclusion

Sedation and polypharmacy were frequent among infants with severe BPD and linked to reduced therapy participation, highlighting the need to assess prescribing rationale and neurodevelopmental impacts.